Vaccine for Diabetes—Where Do We Stand?

Chellappan, DK; Bhandare, RR; Shaik, AB; Prasad, K; Suhaimi, NAA; Yap, WS; Das, A; Banerjee, P; Ghosh, N; Guith, T; Das, A; Balakrishnan, S; Candasamy, M; Mayuren, J; Palaniveloo, K; Gupta, G; Singh, SK; Dua, K

Vaccine for Diabetes—Where Do We Stand?

Chellappan, DK Bhandare, RR Shaik, AB Prasad, K Suhaimi, NAA Yap, WS Das, A Banerjee, P Ghosh, N Guith, T Das, A Balakrishnan, S Candasamy, M Mayuren, J Palaniveloo, K Gupta, G Singh, SK Dua, K

Permalink

Publisher:: MDPI AG
Publication Type:: Journal Article
Citation:: International Journal of Molecular Sciences, 23, (16), pp. 9470-9470

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.51 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Chellappan, DK
dc.contributor.author	Bhandare, RR
dc.contributor.author	Shaik, AB
dc.contributor.author	Prasad, K
dc.contributor.author	Suhaimi, NAA
dc.contributor.author	Yap, WS
dc.contributor.author	Das, A
dc.contributor.author	Banerjee, P
dc.contributor.author	Ghosh, N
dc.contributor.author	Guith, T
dc.contributor.author	Das, A
dc.contributor.author	Balakrishnan, S
dc.contributor.author	Candasamy, M
dc.contributor.author	Mayuren, J
dc.contributor.author	Palaniveloo, K
dc.contributor.author	Gupta, G
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2022-08-24T11:53:04Z
dc.date.available	2022-08-24T11:53:04Z
dc.identifier.citation	International Journal of Molecular Sciences, 23, (16), pp. 9470-9470
dc.identifier.issn	1422-0067
dc.identifier.uri	http://hdl.handle.net/10453/160804
dc.description.abstract	<jats:p>Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.</jats:p>
dc.language	en
dc.publisher	MDPI AG
dc.relation.ispartof	International Journal of Molecular Sciences
dc.relation.isbasedon	10.3390/ijms23169470
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences
dc.subject.classification	Chemical Physics
dc.title	Vaccine for Diabetes—Where Do We Stand?
dc.type	Journal Article
utslib.citation.volume	23
utslib.for	0399 Other Chemical Sciences
utslib.for	0604 Genetics
utslib.for	0699 Other Biological Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	open_access	*
dc.date.updated	2022-08-24T11:53:02Z
pubs.issue	16
pubs.publication-status	Published online
pubs.volume	23
utslib.citation.issue	16

Abstract:

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160804